Stephen J. Williams, Member of the Board, Chief Scientific Officer, Senior Editor, PhD Pharmacology, BSc Toxicology

STEPHEN J. WILLIAMS, Ph.D.

Tel: 215 487 0259 (h)

610 331 1016 (c)

Email: sjwilliamspa@comcast.net

UPDATED on 11/9/2020

Co-Editor Series D, Volume 4:

Human Reproductive System, Genomic Endocrinology and Cancer Types

http://www.amazon.com/dp/B08VTFWVKM

Available on Amazon.com since 2/2/2021
NLP with INTERNS – Proof of Concept – on–going
WIKIPEDIA ENTRY for LPBI & Aviva – REFERENCE GENERATION by 3rd party
AI in Genomics & Cancer – Development of the PORTAL
Interface with Blockchain vendor and NLP two vendors

Personal Bio

Personal Statement: My scientific career has centered on understanding the mechanisms underlying initiation of cancer, as well as the pharmacologic and toxicologic basis of chemotherapy. My research has focused on modeling the etiology and metabolic alterations of human ovarian cancer and malignant mesothelioma, using cellular, molecular and in-vivo strategies. Current research focuses on growth factor cell signaling in mesothelioma. Altogether, my research goals have concentrated on the cellular stresses, and the resultant genetic and metabolic alterations which provide not only a fertile micro-environment for oncogenesis, tumor progression and disease etiology but also an opportunity for therapeutic development

Biography: For the onset of my scientific career I entered one of the first undergraduate toxicology programs in the country, at the Philadelphia College of Pharmacy & Science, and trained in various methodologies in toxicology and pharmacology, including research into effects of leukotrienes and leukotriene antagonists on gastrointestinal motility. I continued with my research training at the University of Pennsylvania Institute for Environmental Medicine, studying the effects of hyperbaric oxygen, and free radicals on lung function and the pathology of Sudden Infant Death Syndrome. I subsequently received my PhD in Pharmacology from Temple University, with my thesis, under Dr. Michael Sirover, involving the biochemical and pharmacologic effects on noncanonical protein functions in metabolism and DNA repair. Afterward, I continued with postdoctoral training in the Department of Pharmacology under an NCI-PRAT fellowship and in the Ovarian Cancer Program in the laboratory of Dr. Thomas Hamilton. My research involved determination of mechanisms of cisplatin resistance in ovarian cancer, discovering genes causal in early ovarian oncogenesis, and development of animal ovarian tumor models useful for determining ovarian cancer driver genes, determining chemotherapeutic efficacy, and development of imaging and surrogate tumor biomarker methods for detection of ovarian tumor burden in in-vivo ovarian cancer models. To this end, I developed one of the first, and patented, porcine ovarian tumor models, and with colleagues, additional models to measure intraperitoneal ovarian cancer using both surrogate tumor markers and MRI imaging methodology useful for chemotherapeutic evaluation.

As scientific research and information was entering a new explosive age of massive data, I decided to assist Dr. Aviva Lev Ari in her venture Leaders in Pharmaceutical Business Intelligence, in developing a methodology of scientific curation, in collaboration with Dr. Larry Bernstein and a worldwide network of expert scientists and clinicians. This effort culminated in the development of an influential web 2.0 platform for the curation, organization, and dissemination of scientific and biomedical findings in addition of the creation of 16 medical e-books on multiple topics. As such I became senior editor on two volumes, an e-book series on Cancer and a series on Genomics.

Concurrently I was designated an adjunct professor in Temple University College of Science & Technology, teaching a course on Cell Signaling and Cancer Biology, as well as an associate professor in the Sbarro Health Research Organization where I head the grants department including grants management and administration. Currently I also decided to continue my research efforts into understanding events causal in early oncogenesis and joined the research organization ISOPROG, where we have been researching autocrine growth factor loops involved in the malignant phenotype in mesothelioma and other cancer types.

As a result of the aforementioned endeavors, I have multiple peer-reviewed publications and book chapters as well as whole books in the fields of cancer, genomics, and personalized oncology. In addition, I am a frequent reviewer for such journals such as Cancer Research, Cancers, the Journal of Cellular Physiology, and others. I am a member of the AAAS, AACR, Mid Atlantic Pharmacology and Mid Atlantic Toxicology Society.

AREAS OF EXPERTISE

Molecular Biology and Biochemistry: Transitional research, recombinant DNA technologies; RNA/DNA purification and analysis; real-time PCR and primer design; DNA methylation; Western analysis (quantative); ELISA; DNA repair assays; enzyme kinetics; analysis of cellular redox status; protein modification; enzyme and protein purification; column chromatography; HPLC; immunohistochemistry; reporter gene assays.
Cellular: Primary cell culture and isolation; development and establishment of cell lines (primary and tumorigenic, stable lines generation); flow cytometry; Guava single cell analysis; soft agar colony assay; cell proliferation/toxicity assays; in-vitro transformation.
In-Vivo: Small animal handling and colony maintenance; development of animal models of ovarian cancer; in-vivo preclinical drug evaluation; necropsy and gross pathology; small animal imaging.

Curriculum Vitae

SCIENCE Side Member

Responsibilities @LPBI:

(1) Curator initiated new content creation

(2) Updates to own published articles in the Journal

(3) Commissions by the Editor-in-Chief – One curation per WEEK

(4) Client facing engagement with External relations

(5) Advice for the Founder

Roles on 2.0 LPBI Group’s TNS #1,2,3,4,5,6 https://pharmaceuticalintelligence.com/vision/

(1) TNS #1: https://www.wolfram.com/featureset/machine-learning/

1.1 LPBI LEAD on Comparison of NLP results obtained for Microsoft AZURE and EXPERIMENT with Text Analysis The Wolfram Language

1.2 LPBI LEAD on Application on the ingress TEXT from: Cancer Volume 1 &2 and Genomics Volume 1&2

1.3 LPBI LEAD on Phase 3: Scaling up NLP, ML, AI to LPBI Group’s FOUR Corpuses Using LPBI’s Vendor of Choice:

The Wolfram Solution for Biological Sciences
The Wolfram Data Drop is an open service that makes it easy to accumulate data of any kind, from anywhere—setting it up for immediate computation, visualization, analysis, querying, or other operations

(2) TNS #2: Blockchain Transactions and broadcasting to communities in the Health Care Sector – THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: BustIQ – lined them up and are willing to build the Front End

(3) Co-Editor LPBI Group’s BioMed Book #17 – COMPLETE Editorials by 12/10/2020